A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
- Study Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
- Teva Identifier
- TV48125-MH-40142 | 2019-001989-15
- ClinicalTrials.gov Identifier
- NCT04041284
- Study Status
- Completed
- Trial Condition(s)
- Migraine | Major Depressive Disorder
- Interventions
- Drug: Fremanezumab | Drug: Placebo
- EudraCT Number
- 2019-001989-15
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- September 13, 2019 - August 31, 2022
- Phase
- Phase 4